ScholarLens Back to search
2010•Yixue yanjiusheng xuebaoRequires access

Progress of the XELOX regimen applied in gastrointestinal cancer

Dong Zhang-xia

Open publisher page 0 citations

Abstract

The combination of Oxaliplatin and Capecitabine(XELOX)has a synergic effect,which was demonstrated non-inferior to the FOLFOX regimens.The regimen has a activated effect that served as adjuvant therapy,neoadjuvant therapy and the first-line therapy in colorectal cancer,and had been applied in the advanced gastric cancer and other gastrointestinal cancers.The XELOX regimen was toxicity well tolerant and more convenient to administer than FOLFOX regimens,thus the application is continually increasing.This review presented the recent progression in the application of XELOX regimen in gastrointestinal cancers.

About this research paper

What this paper is about

The combination of Oxaliplatin and Capecitabine(XELOX)has a synergic effect,which was demonstrated non-inferior to the FOLFOX regimens.The regimen has a activated effect that served as adjuvant therapy,neoadjuvant therapy and the first-line therapy in colorectal cancer,and had been applied in the advanced gastric cancer and other gastrointestinal cancers.The XELOX regimen was toxicity well tolerant and more convenient to administer than FOLFOX regimens,thus the application is continually increasing.This review presented the recent progression in the application of XELOX regimen in gastrointestinal cancers.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The combination of Oxaliplatin and Capecitabine(XELOX)has a synergic effect,which was demonstrated non-inferior to the FOLFOX regimens.The regimen has a activated effect that served as adjuvant therapy,neoadjuvant therapy and the first-line therapy in colorectal cancer,and had been applied in the advanced gastric cancer and other gastrointestinal cancers.The XELOX regimen was toxicity well tolerant and more convenient to administer than FOLFOX regimens,thus the application is continually increasing.This review presented the recent progression in the application of XELOX regimen in gastrointestinal cancers.

Key concepts: Oxaliplatin, Capecitabine, Regimen, FOLFOX, Medicine, Colorectal cancer, Oncology, Internal medicine

Back to paper searchBrowse research topicsOriginal source
Progress of the XELOX regimen applied in gastrointestinal cancer — Research Paper | ScholarLens